Depression affects approximately 280 million people all over the world, and disproportionately affects the female population — it is 50% more common in women than men. Treatments range from psychotherapy and lifestyle adjustments to antidepressants and more experimental concepts: brain stimulation therapies. Sooma, a medtech startup based in Helsinki, Finland, is focused on the latter. The company has developed a portable brain stimulation device for Transcranial Direct Current Stimulation (tDCS). Its neuromodulation device is already the most prescribed tDCS therapy worldwide, with over 20,000 people having received treatment. Sooma announced today it has secured additional growth funding of €5mn to…
This story continues at The Next Web